Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Overview

About this study

The purpose of this study is to test a new technology called Next Generation Sequencing (NGS) that may help identify this risk associated with precursor conditions and the likelihood that they will change into overt blood and bone marrow cancers. NGS is a procedure that looks at relevant cancer associated genes and what they do.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients with idiopathic cytopenias of unclear significance (ICUS).
Patients with clonal hematopoiesis of indeterminate significance (CHIP).
Patients with clonal cytopenias of unclear significance.
Marrow failure syndromes with myeloid malignancy predisposition – telomere dysfunction, chromosomal breakage disorders.
Germ line inherited syndromes with risk for malignant transformation – GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6 etc.
Low Risk MDS (idiopathic dysplasia of unclear significance).
Family member of a patient with one of the above conditions.

Exclusion Criteria:

Patients under 18 years of age.
Reconsenting of participants may be made by a telephone call with an IRB approved telephone script from the Rochester, Arizona, or Florida location, electronic remote, electronic digital in person, or a mail out consent form so we will not add undo stress to participants.

Eligibility last updated 3/23/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Mrinal Patnaik, M.B.B.S.	Open for enrollment	Contact information: Caleb Hammel R.T.(MR) (507) 538-6691 Hammel.Caleb@mayo.edu
Jacksonville, Fla. Mayo Clinic principal investigator James Foran, M.D.	Open for enrollment	Contact information: Poh Ching Chia (904) 953-8508 Chia.PohChing@mayo.edu
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Cecilia Arana Yi, M.D.	Open for enrollment	Contact information: Caleb Hammel R.T.(MR) (507) 538-6691 Hammel.Caleb@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mrinal Patnaik, M.B.B.S.

Open for enrollment

Contact information:

Caleb Hammel R.T.(MR)

(507) 538-6691

Hammel.Caleb@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

James Foran, M.D.

Open for enrollment

Contact information:

Poh Ching Chia

(904) 953-8508

Chia.PohChing@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Cecilia Arana Yi, M.D.

Open for enrollment

Contact information:

Caleb Hammel R.T.(MR)

(507) 538-6691

Hammel.Caleb@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials